The Predictive Value of Blood-Derived Exosomal miRNAs as Biomarkers in Breast Cancer: A Systematic Review
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2024.06.016 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Marina Linares-Rodríguez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, Granada, Spain. Hauptthemen laut MEDLINE: Breast Neoplasms, Biomarkers, Tumor, MicroRNAs, Exosomes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Consejería de Salud y Familias, Junta de Andalucía, Junta de Andalucia Consejeria de Salud y Familias.
Abstract (Originalsprache)
Breast cancer (BC) remains a widespread disease worldwide, despite advances in its detection and treatment. microRNAs (miRNAs) play a significant role in cancer, and their presence within exosomes may confer several advantages in terms of tumor initiation, propagation, immune evasion, and drug resistance compared to freely circulating miRNAs in the blood. The objective of this study was to conduct a systematic review to analyze the role of exosomal miRNAs present in serum or plasma as biomarkers in BC. Bibliographic sources were collected from various databases with no starting date limit until March 2023. The search terms used were related to "breast cancer," "microRNAs," and "exosomes." Following the search, inclusion and exclusion criteria were applied, resulting in a total of 46 articles. Data were extracted from the selected studies and summarized to indicate the miRNAs, type of dysregulation, sample source, number of patients and controls, and clinical relevance of the miRNAs. We carried out an enrichment study of the microRNAs that appeared in at least 3 studies, those that were suitable for selection were miR-16, miR-21 and miR-155. Exosomal miRNAs isolated from blood samples of patients diagnosed with BC could be valuable in the clinical setting. They could provide information about early diagnosis, disease progression, recurrence, treatment response, and metastases. It is crucial to reach a consensus on the specific exosomal miRNAs to detect and the most appropriate type of sample for comprehensive utilization of miRNAs as biomarkers for BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, Granada, Spain.
- Department of Medicine, School of Medicine, University of Granada, Granada, Spain; Department of Medical Oncology, San Cecilio University Hospital, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (ibs…
- Biopathology and Regenerative Medicine Institute (IBIMER), University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain; Department of Human Anatomy and Embryol…
Förderung
- Consejería de Salud y Familias, Junta de Andalucía
- Junta de Andalucia Consejeria de Salud y Familias
Zitieren
APA
Linares-Rodríguez, M., Blancas, I., & Rodríguez-Serrano, F. (2025). The Predictive Value of Blood-Derived Exosomal miRNAs as Biomarkers in Breast Cancer: A Systematic Review. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.06.016
Vancouver
Linares-Rodríguez M, Blancas I, Rodríguez-Serrano F. The Predictive Value of Blood-Derived Exosomal miRNAs as Biomarkers in Breast Cancer: A Systematic Review. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2024.06.016
BibTeX
@article{LinaresRodrguez2025,
author = {Linares-Rodríguez, Marina and Blancas, Isabel and Rodríguez-Serrano, Fernando},
title = {The Predictive Value of Blood-Derived Exosomal miRNAs as Biomarkers in Breast Cancer: A Systematic Review},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2024.06.016}
}
EUVIMED